Boston Scientific Chairman, President and CEO Michael F. Mahoney purchased 208,359 shares of the company's common stock for a total transaction value of $10.1 million, according to an SEC filing. The purchase, executed on August 3, 2026, at a weighted average price of $48.34 per share, expands Mahoney's total equity interest by 13% to approximately 1.6 million shares valued at $78.08 million based on that day's close. The acquisition was made through multiple trades at prices ranging from $47.87 to $48.47, with most shares bought directly and about 22,000 shares acquired through a discretionary rebalancing within the company's 401(k) Retirement Savings Plan. The transaction follows a period of negative price momentum, with Boston Scientific recording a -54% return over the prior 12 months, and comes after management twice cut revenue guidance in 2026 due to a competitive marketplace. The company, which has a market capitalization of $73 billion and trailing twelve-month revenue of $21 billion, is looking to a brighter future with a robust pipeline of new products expected from 2027 through 2029 and a restructuring aimed at cutting $500 million in costs.
Boston Scientific CorpCEO's $10M insider purchase signals confidence despite recent struggles.
